Therapeutic Vaccines Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Technology, End User, and Geography

Description

List of Tables

The therapeutic vaccines market size is expected to grow from US$ 1.24 billion in 2024 to US$ 2.93 billion by 2031; it is projected to register a CAGR of 13.0% during 2024-2031. The rising prevalence of chronic diseases, and increasing investments and funding for vaccine development are noteworthy factors contributing to the expansion of the therapeutic vaccines market size. However, regulatory challenges hinder the therapeutic vaccines market growth.

Developing vaccines against emerging pathogens that possess the potential to cause pandemics is not feasible using conventional technologies. As a result, it is important to develop platforms that can respond rapidly to pandemic threats and adapt effectively to measures taken to tackle emerging variants. Innovative vaccine platforms-such as mRNA vaccines, immuno-material-based vaccine technology, nano-drug delivery systems, and viral vector-based vaccines-are revolutionizing the development of therapeutic vaccines. Further, the shift toward more efficient and customizable vaccine technologies has enabled the development of vaccines that can target several diseases, including cancers, autoimmune conditions, and infectious diseases. The success of mRNA COVID-19 vaccine technology showcases promises in the potential of mRNA technology for therapeutic applications beyond infectious diseases, including cancer and chronic infections. These platforms allow for quicker, more flexible, and better scalable vaccine production, accelerating the development of new therapeutic vaccines.

Researchers are developing novel platforms for future applications. For instance, a research team at the Wyss Institute at Harvard University is developing a pioneering vaccine platform known as OMNIVAX. This "first-in-class immuno-material-based" vaccine technology aims to create safe and effective therapeutic and prophylactic vaccines against viral and bacterial infections. Upon injection, OMNIVAX vaccines establish a scaffold to attract dendritic immune cells, programming them to target a specific antigen. The cells are then released, followed by their migration to nearby lymph nodes, where they initiate a systemic and prolonged immune response. Using modular technology, multiple antigens can be incorporated into a single OMNIVAX vaccine. The advancements in vaccine technology are likely to bring new trends in the therapeutic vaccines market in the coming years.

End User-Based Insights

Based on end user, the therapeutic vaccines market is segmented into hospitals, clinics, and others. The hospitals segment held the largest therapeutic vaccines market share in 2024. Therapeutic vaccines are increasingly being recognized as a critical part of the treatment of cancer and other chronic diseases, which are frequently managed in hospital settings. Hospitals are equipped with the advanced infrastructure required to administer specialized therapies against cancer and autoimmune diseases. As the prevalence of chronic diseases, including cancer, continues to rise globally, hospitals generate a persistent demand for these treatments. Hospitals offer comprehensive care, including diagnostic services, treatment, and post-therapy monitoring, all of which are crucial for patients undergoing therapeutic vaccine treatments. Additionally, an upsurge in hospital-based research and clinical trials contributes to the expansion of the therapeutic vaccines market for this segment. Many therapeutic vaccines undergo trials within hospital environments, enabling healthcare professionals to stay updated on the development of new vaccines and treatments, fueling the therapeutic vaccines market growth.

World Health Organization's (WHO), Global Cancer Facts & Figures, and the American Cancer Society are among the primary and secondary sources referred to while preparing the therapeutic vaccines market report.

Product Code: TIPRE00039849

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Therapeutic Vaccines Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Therapeutic Vaccines Market - Key Market Dynamics

5.1 Therapeutic Vaccines Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Rising Prevalence of Chronic Conditions
- 5.2.2 Increasing Investments and Funding for Vaccine Development
5.3 Market Restraints
- 5.3.1 Regulatory Challenges
5.4 Market Opportunities
- 5.4.1 Extending Product Pipeline
5.5 Future Trends
- 5.5.1 Advancements in Vaccine Technology
5.6 Impact of Drivers and Restraints:

6. Therapeutic Vaccines Market - Global Market Analysis

6.1 Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
6.2 Therapeutic Vaccines Market Forecast Analysis

7. Therapeutic Vaccines Market Analysis - by Product

7.1 Cancer Vaccines
- 7.1.1 Overview
- 7.1.2 Cancer Vaccines: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
7.2 Infectious Disease Vaccines
- 7.2.1 Overview
- 7.2.2 Infectious Disease Vaccines: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
7.3 Others
- 7.3.1 Overview
- 7.3.2 Others: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)

8. Therapeutic Vaccines Market Analysis - by Technology

8.1 Allogenic Vaccine
- 8.1.1 Overview
- 8.1.2 Allogenic Vaccine: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
8.2 Autologous Vaccine
- 8.2.1 Overview
- 8.2.2 Autologous Vaccine: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)

9. Therapeutic Vaccines Market Analysis - by End User

9.1 Hospitals
- 9.1.1 Overview
- 9.1.2 Hospitals: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
9.2 Clinics
- 9.2.1 Overview
- 9.2.2 Clinics: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
9.3 Others
- 9.3.1 Overview
- 9.3.2 Others: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)

10. Therapeutic Vaccines Market - Geographical Analysis

10.1 North America
- 10.1.1 North America Therapeutic Vaccines Market Overview
- 10.1.2 North America: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  - 10.1.2.1 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
  - 10.1.2.2 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.1.2.3 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
- 10.1.3 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.1.3.1 United States: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.1.3.1.1 United States: Therapeutic Vaccines Market Breakdown, by Product
    - 10.1.3.1.2 United States: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.1.3.1.3 United States: Therapeutic Vaccines Market Breakdown, by End User
  - 10.1.3.2 Canada: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.1.3.2.1 Canada: Therapeutic Vaccines Market Breakdown, by Product
    - 10.1.3.2.2 Canada: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.1.3.2.3 Canada: Therapeutic Vaccines Market Breakdown, by End User
  - 10.1.3.3 Mexico: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.1.3.3.1 Mexico: Therapeutic Vaccines Market Breakdown, by Product
    - 10.1.3.3.2 Mexico: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.1.3.3.3 Mexico: Therapeutic Vaccines Market Breakdown, by End User
10.2 Europe
- 10.2.1 Europe Therapeutic Vaccines Market Overview
- 10.2.2 Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  - 10.2.2.1 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
  - 10.2.2.2 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.2.2.3 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
- 10.2.3 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.2.3.1 Germany: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.2.3.1.1 Germany: Therapeutic Vaccines Market Breakdown, by Product
    - 10.2.3.1.2 Germany: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.2.3.1.3 Germany: Therapeutic Vaccines Market Breakdown, by End User
  - 10.2.3.2 United Kingdom: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.2.3.2.1 United Kingdom: Therapeutic Vaccines Market Breakdown, by Product
    - 10.2.3.2.2 United Kingdom: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.2.3.2.3 United Kingdom: Therapeutic Vaccines Market Breakdown, by End User
  - 10.2.3.3 France: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.2.3.3.1 France: Therapeutic Vaccines Market Breakdown, by Product
    - 10.2.3.3.2 France: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.2.3.3.3 France: Therapeutic Vaccines Market Breakdown, by End User
  - 10.2.3.4 Italy: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.2.3.4.1 Italy: Therapeutic Vaccines Market Breakdown, by Product
    - 10.2.3.4.2 Italy: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.2.3.4.3 Italy: Therapeutic Vaccines Market Breakdown, by End User
  - 10.2.3.5 Spain: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.2.3.5.1 Spain: Therapeutic Vaccines Market Breakdown, by Product
    - 10.2.3.5.2 Spain: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.2.3.5.3 Spain: Therapeutic Vaccines Market Breakdown, by End User
  - 10.2.3.6 Rest of Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.2.3.6.1 Rest of Europe: Therapeutic Vaccines Market Breakdown, by Product
    - 10.2.3.6.2 Rest of Europe: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.2.3.6.3 Rest of Europe: Therapeutic Vaccines Market Breakdown, by End User
10.3 Asia Pacific
- 10.3.1 Asia Pacific Therapeutic Vaccines Market Overview
- 10.3.2 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  - 10.3.2.1 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
  - 10.3.2.2 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.3.2.3 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
- 10.3.3 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.3.3.1 China: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.3.3.1.1 China: Therapeutic Vaccines Market Breakdown, by Product
    - 10.3.3.1.2 China: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.3.3.1.3 China: Therapeutic Vaccines Market Breakdown, by End User
  - 10.3.3.2 Japan: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.3.3.2.1 Japan: Therapeutic Vaccines Market Breakdown, by Product
    - 10.3.3.2.2 Japan: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.3.3.2.3 Japan: Therapeutic Vaccines Market Breakdown, by End User
  - 10.3.3.3 India: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.3.3.3.1 India: Therapeutic Vaccines Market Breakdown, by Product
    - 10.3.3.3.2 India: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.3.3.3.3 India: Therapeutic Vaccines Market Breakdown, by End User
  - 10.3.3.4 South Korea: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.3.3.4.1 South Korea: Therapeutic Vaccines Market Breakdown, by Product
    - 10.3.3.4.2 South Korea: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.3.3.4.3 South Korea: Therapeutic Vaccines Market Breakdown, by End User
  - 10.3.3.5 Australia: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.3.3.5.1 Australia: Therapeutic Vaccines Market Breakdown, by Product
    - 10.3.3.5.2 Australia: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.3.3.5.3 Australia: Therapeutic Vaccines Market Breakdown, by End User
  - 10.3.3.6 Rest of APAC: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.3.3.6.1 Rest of APAC: Therapeutic Vaccines Market Breakdown, by Product
    - 10.3.3.6.2 Rest of APAC: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.3.3.6.3 Rest of APAC: Therapeutic Vaccines Market Breakdown, by End User
10.4 Middle East & Africa
- 10.4.1 Middle East & Africa Therapeutic Vaccines Market Overview
- 10.4.2 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  - 10.4.2.1 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
  - 10.4.2.2 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.4.2.3 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
- 10.4.3 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.4.3.1 Saudi Arabia: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.4.3.1.1 Saudi Arabia: Therapeutic Vaccines Market Breakdown, by Product
    - 10.4.3.1.2 Saudi Arabia: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.4.3.1.3 Saudi Arabia: Therapeutic Vaccines Market Breakdown, by End User
  - 10.4.3.2 South Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.4.3.2.1 South Africa: Therapeutic Vaccines Market Breakdown, by Product
    - 10.4.3.2.2 South Africa: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.4.3.2.3 South Africa: Therapeutic Vaccines Market Breakdown, by End User
  - 10.4.3.3 United Arab Emirates: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.4.3.3.1 United Arab Emirates: Therapeutic Vaccines Market Breakdown, by Product
    - 10.4.3.3.2 United Arab Emirates: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.4.3.3.3 United Arab Emirates: Therapeutic Vaccines Market Breakdown, by End User
  - 10.4.3.4 Rest of Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.4.3.4.1 Rest of Middle East & Africa: Therapeutic Vaccines Market Breakdown, by Product
    - 10.4.3.4.2 Rest of Middle East & Africa: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.4.3.4.3 Rest of Middle East & Africa: Therapeutic Vaccines Market Breakdown, by End User
10.5 South & Central America
- 10.5.1 South & Central America Therapeutic Vaccines Market Overview
- 10.5.2 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  - 10.5.2.1 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
  - 10.5.2.2 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.5.2.3 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
- 10.5.3 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.5.3.1 Brazil: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.5.3.1.1 Brazil: Therapeutic Vaccines Market Breakdown, by Product
    - 10.5.3.1.2 Brazil: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.5.3.1.3 Brazil: Therapeutic Vaccines Market Breakdown, by End User
  - 10.5.3.2 Argentina: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.5.3.2.1 Argentina: Therapeutic Vaccines Market Breakdown, by Product
    - 10.5.3.2.2 Argentina: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.5.3.2.3 Argentina: Therapeutic Vaccines Market Breakdown, by End User
  - 10.5.3.3 Rest of South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 10.5.3.3.1 Rest of South & Central America: Therapeutic Vaccines Market Breakdown, by Product
    - 10.5.3.3.2 Rest of South & Central America: Therapeutic Vaccines Market Breakdown, by Technology
    - 10.5.3.3.3 Rest of South & Central America: Therapeutic Vaccines Market Breakdown, by End User

11. Therapeutic Vaccines Market - Industry Landscape

11.1 Overview
11.2 Growth Strategies in the Therapeutic Vaccines Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Dendreon
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 BioNTech SE
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Serum Institute of India Pvt. Ltd
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Merck & Co Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Amgen Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 ISA Pharmaceuticals BV
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 INOVIO Pharmaceuticals Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Transgene SA
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 THERAVECTYS SA
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 CureVac SE
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms